Unknown

Dataset Information

0

Allele-Specific CRISPR/Cas9 Correction of a Heterozygous DNM2 Mutation Rescues Centronuclear Myopathy Cell Phenotypes.


ABSTRACT: Genome editing with the CRISPR/Cas9 technology has emerged recently as a potential strategy for therapy in genetic diseases. For dominant mutations linked to gain-of-function effects, allele-specific correction may be the most suitable approach. In this study, we tested allele-specific inactivation or correction of a heterozygous mutation in the Dynamin 2 (DNM2) gene that causes the autosomal dominant form of centronuclear myopathies (CNMs), a rare muscle disorder belonging to the large group of congenital myopathies. Truncated single-guide RNAs targeting specifically the mutated allele were tested on cells derived from a mouse model and patients. The mutated allele was successfully targeted in patient fibroblasts and Dnm2R465W/+ mouse myoblasts, and clones were obtained with precise genome correction or inactivation. Dnm2R465W/+ myoblasts showed an alteration in transferrin uptake and autophagy. Specific inactivation or correction of the mutated allele rescued these phenotypes. These findings illustrate the potential of CRISPR/Cas9 to target and correct in an allele-specific manner heterozygous point mutations leading to a gain-of-function effect, and to rescue autosomal dominant CNM-related phenotypes. This strategy may be suitable for a large number of diseases caused by germline or somatic mutations resulting in a gain-of-function mechanism.

SUBMITTER: Rabai A 

PROVIDER: S-EPMC6439232 | biostudies-literature | 2019 Jun

REPOSITORIES: biostudies-literature

altmetric image

Publications

Allele-Specific CRISPR/Cas9 Correction of a Heterozygous DNM2 Mutation Rescues Centronuclear Myopathy Cell Phenotypes.

Rabai Aymen A   Reisser Léa L   Reina-San-Martin Bernardo B   Mamchaoui Kamel K   Cowling Belinda S BS   Nicot Anne-Sophie AS   Laporte Jocelyn J  

Molecular therapy. Nucleic acids 20190227


Genome editing with the CRISPR/Cas9 technology has emerged recently as a potential strategy for therapy in genetic diseases. For dominant mutations linked to gain-of-function effects, allele-specific correction may be the most suitable approach. In this study, we tested allele-specific inactivation or correction of a heterozygous mutation in the Dynamin 2 (DNM2) gene that causes the autosomal dominant form of centronuclear myopathies (CNMs), a rare muscle disorder belonging to the large group of  ...[more]

Similar Datasets

| S-EPMC6205463 | biostudies-literature
| S-EPMC4530644 | biostudies-literature
| S-EPMC9016898 | biostudies-literature
| S-EPMC5507568 | biostudies-literature
| S-EPMC10863003 | biostudies-literature
| S-EPMC3938268 | biostudies-literature
| S-EPMC2991611 | biostudies-literature
| S-EPMC5801507 | biostudies-literature
| S-EPMC3469422 | biostudies-literature
| S-EPMC2572588 | biostudies-literature